329 related articles for article (PubMed ID: 15852024)
1. Lower incidence of Bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning.
Yoshihara S; Tateishi U; Ando T; Kunitoh H; Suyama H; Onishi Y; Tanosaki R; Mineishi S
Bone Marrow Transplant; 2005 Jun; 35(12):1195-200. PubMed ID: 15852024
[TBL] [Abstract][Full Text] [Related]
2. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.
Nakamae H; Yamane T; Hasegawa T; Nakamae M; Terada Y; Hagihara K; Ohta K; Hino M
Am J Hematol; 2006 Jul; 81(7):525-31. PubMed ID: 16755559
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens.
Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
Bone Marrow Transplant; 2009 Jun; 43(12):949-51. PubMed ID: 19104492
[TBL] [Abstract][Full Text] [Related]
5. Donor lymphocyte infusion may reduce the incidence of bronchiolitis obliterans after allogeneic stem cell transplantation.
Forslöw U; Mattsson J; Gustafsson T; Remberger M
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1214-21. PubMed ID: 21193056
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
[TBL] [Abstract][Full Text] [Related]
7. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
[TBL] [Abstract][Full Text] [Related]
8. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
[TBL] [Abstract][Full Text] [Related]
9. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic myeloablative transplantation for patients aged 50 years and over.
Yanada M; Emi N; Naoe T; Sakamaki H; Iseki T; Hirabayashi N; Karasuno T; Chiba S; Atsuta Y; Hamajima N; Takahashi S; Kato S
Bone Marrow Transplant; 2004 Jul; 34(1):29-35. PubMed ID: 15156161
[TBL] [Abstract][Full Text] [Related]
11. Chronic kidney disease after myeloablative allogeneic hematopoietic stem cell transplantation.
Kersting S; Hené RJ; Koomans HA; Verdonck LF
Biol Blood Marrow Transplant; 2007 Oct; 13(10):1169-75. PubMed ID: 17889353
[TBL] [Abstract][Full Text] [Related]
12. Late-onset non-infectious pulmonary complications following allogeneic hematopoietic stem cell transplantation in children.
Nishio N; Yagasaki H; Takahashi Y; Muramatsu H; Hama A; Tanaka M; Yoshida N; Watanabe N; Kudo K; Yoshimi A; Kojima S
Bone Marrow Transplant; 2009 Sep; 44(5):303-8. PubMed ID: 19349954
[TBL] [Abstract][Full Text] [Related]
13. Bronchiolitis obliterans after allogeneic hematopoietic SCT: further insight--new perspectives?
Ditschkowski M; Elmaagacli AH; Koldehoff M; Gromke T; Trenschel R; Beelen DW
Bone Marrow Transplant; 2013 Sep; 48(9):1224-9. PubMed ID: 23435515
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
15. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease.
Yanada M; Naoe T; Iida H; Sakamaki H; Sakura T; Kanamori H; Kodera Y; Okamoto S; Kanda Y; Sao H; Asai O; Nakai K; Maruta A; Kishi K; Furukawa T; Atsuta Y; Yamamoto K; Tanaka J; Takahashi S
Bone Marrow Transplant; 2005 Nov; 36(10):867-72. PubMed ID: 16113659
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of serum surfactant protein D level prior to transplant for the development of bronchiolitis obliterans syndrome and idiopathic pneumonia syndrome following allogeneic hematopoietic stem cell transplantation.
Nakane T; Nakamae H; Kamoi H; Koh H; Takeoka Y; Sakamoto E; Kanashima H; Nakamae M; Ohta K; Terada Y; Koh KR; Yamane T; Hino M
Bone Marrow Transplant; 2008 Jul; 42(1):43-9. PubMed ID: 18347569
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
18. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation.
Kataoka K; Nannya Y; Hangaishi A; Imai Y; Chiba S; Takahashi T; Kurokawa M
Biol Blood Marrow Transplant; 2009 Feb; 15(2):195-204. PubMed ID: 19167679
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo T-cell depletion with myeloablative or reduced-intensity conditioning in pediatric hematopoietic stem cell transplantation.
Seidel MG; Fritsch G; Matthes-Martin S; Lawitschka A; Lion T; Pötschger U; Rosenmayr A; Fischer G; Gadner H; Peters C
Haematologica; 2005 Oct; 90(10):1405-14. PubMed ID: 16219578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
